Evidence map›Paper›PMID 42326338›Full record

ArticleFrontiers in oncology2026

Integrative oncology: evolution, framework, and future directions.

Lorenzo Cohen, Eran Ben-Arye

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lorenzo CohenDepartment of Palliative, Rehabilitation, & Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Eran Ben-AryeIntegrative Oncology Program, The Oncology Service, Lin-Carmel-Zebulun Medical Centers, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past several decades, cancer treatment has evolved from a discipline centered almost exclusively on tumor-directed modalities to one that increasingly acknowledges the complex interplay of biological, behavioral, psychosocial, spiritual, cultural, and environmental factors that shape patient outcomes. This shift has set the stage for the rise of integrative oncology: an evidence-informed, patient-centered approach that combines mind-body practices, natural products, and lifestyle strategies with conventional cancer treatment to enhance wellbeing, manage symptoms, and improve quality of life across the cancer continuum. Although rooted in long-standing healing traditions, integrative oncology emerged as a modern clinical and scientific field in response to patient needs, health-belief models, growing research evidence, and recognition of the limitations of a purely biomedical framework. There is also a need to mitigate the risks associated with unmonitored "alternative medicine" use and to ensure that trained healthcare professionals foster open, non-judgmental, evidence-based, patient-centered discussions regarding the use of integrative modalities in high-risk oncology and surgical settings. The formation of the Society for Integrative Oncology, development of evidence-informed clinical guidelines, and increasing adoption within major cancer centers have collectively advanced the discipline and established standards for safe and effective care. As the field matures, challenges remain including disparities in access, gaps in education, and the need for rigorous whole-systems research. This introductory manuscript to the special issue outlines the historical trajectory, scientific foundations, clinical models, and future opportunities that define integrative oncology today and its potential to transform cancer care.

Indexed as

integrative medicinelifestyleoncologyquality of lifesafetysurvivorship

Identifiers

PMID42326338
PMCPMC13278935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.